HK1079103A - A photoprotective orally administrable composition for skin - Google Patents

Description

Orally administrable photoprotective compositions for the skin

Technical Field

The present invention relates to orally administrable or pharmaceutical or cosmetic compositions for the photoprotection of the skin before, during and/or after exposure to UV radiation and the use of such compositions for preventing and/or reducing the damage caused by such UV radiation. The invention also relates to a method of improving photoprotection of the skin.

The present invention more particularly relates to the aforementioned photoprotective compositions comprising, in an orally acceptable excipient, carrier or diluent, a photoprotecting effective amount of i) at least one yeast and ii) at least one probiotic lactic acid bacterial strain.

Background

The continuous reduction of the atmospheric ozone layer and the simultaneous increase of ultraviolet radiation reaching the earth's surface has attracted great interest for its potential role in human health.

Indeed, it is known that light radiation (UV-A) with a wavelength of 320nm to 400nm promotes tanning of the human epidermis; however, such radiation may cause skin damage, particularly to sensitive skin or skin that is constantly exposed to solar radiation. UV-A radiation can lead, in particular, to a loss of skin elasticity and the appearance of wrinkles, promoting premature aging thereof. It is also known in the art that light having a wavelength of 280nm to 320nm (UV-B) causes erythema and skin sunburn, which can impair the natural appearance of skin tone after sun exposure.

Although humans require exposure to ultraviolet radiation to produce vitamin D, there is increasing evidence that excessive exposure to sunlight, particularly ultraviolet radiation, leads to various skin problems, including induction of certain skin cancers and induction of accelerated skin aging.

In addition to these established health problems, studies also provide evidence that exposure to ultraviolet radiation can negatively affect various immune responses of an organism both locally (in the ultraviolet-irradiated skin) and systemically (i.e., away from the irradiated skin).

Therefore, in order to maintain suitable skin quality after exposure to ultraviolet radiation, it is necessary to prevent or treat the skin prior to exposure, to protect the skin during exposure, and even to mitigate the deleterious effects of ultraviolet radiation on the skin, to prevent erythema, edema, and/or flaking or scaling (hyperkeratosis) of the skin.

In the prior art, there have been some attempts to use sunscreens or other specific agents.

Topical application of ultraviolet radiation absorbing compounds (sunscreens) is reported in j.invest.dermaltol, 97(1991), 624-. This finding was confirmed by several other studies according to which sunscreens appear to prevent inflammation or irritation but the immunosuppressive effect on uv radiation does not provide complete prophylactic protection.

On the other hand, it is shown in FR 2698268 (L' Oreal) that an orally administrable composition comprising a combination of at least one amino acid, a copper salt and a mixture of vitamins exerts a UV-protective effect on the skin.

However, there remains a need in the art for orally administrable compositions that can enhance and/or enhance the photoprotective function of skin.

Summary of The Invention

Accordingly, in a first aspect, the present invention aims to provide an orally administrable composition for skin photoprotection comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast, included in an orally acceptable carrier.

The invention also relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one yeast, comprised in an orally acceptable carrier, for the preparation of an orally administrable composition for protecting the skin against solar radiation and for reducing or preventing all the relevant skin disorders, such as erythema, inflammation, sunburn, barrier function (barrier function), photoaging, alterations of the immune system.

Finally, the present invention relates to a method for improving the photoprotective function of the skin, comprising orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast, in an orally acceptable carrier.

The combination according to the invention has a particularly beneficial effect on skin protection and skin colour formation, which helps to alleviate the relevant stressful effects of solar radiation on the skin.

Detailed Description

In the following description, "NCC" refers to Nestle filtration Collection (Nestle research center, Vers-chez-les-Blanc, Lausane, Switzerland). The term "photoprotection" is used to describe attempts to prevent or mitigate the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.

According to the invention, the composition of the invention comprises as active agent a combined mixture of at least one probiotic lactic acid bacterium or bifidobacterium or a culture supernatant thereof and at least one yeast.

Indeed, it has now surprisingly and unexpectedly been determined that the mixing of these two very specific ingredients can cause an enhanced effect or response in the photoprotection of the skin.

Probiotic organisms are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. After continued ingestion by the host, they may eventually substantially colonize the gut, competing with other potential pathogenic bacteria for nutrients and/or attachment sites on the gastrointestinal wall and reducing the number of pathogenic bacteria and reducing or preventing infection. To date, many different probiotic micro-organisms have been discovered, all of which have been reported to exert their effects in the gut by producing toxins, metabolic by-products, short chain fatty acids, and the like.

It is now shown that probiotic organisms also act in locations in the body of an individual that are remote from the area in which they colonise. Furthermore, it has been surprisingly found that a composition having a synergistic photoprotective effect on the skin can be obtained by combining a probiotic microorganism and a yeast in an orally acceptable carrier.

In a preferred embodiment, the probiotic organism to be comprised in the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacillus (Lactobacillus) and/or Bifidobacterium (Bifidobacterium), more preferably Lactobacillus jensenii (Lactobacillus johnsonii), Lactobacillus reuteri (Lactobacillus reuteri), Lactobacillus rhamnosus (Lactobacillus rhamnoides), Lactobacillus paracasei, Lactobacillus casei (Lactobacillus casei) or Bifidobacterium bifidum (Bifidobacterium bifidum), Lactobacillus brevis (Bifidobacterium breve), Bifidobacterium longum (Bifidobacterium longum), Bifidobacterium animalis, Lactobacillus bifidum (Bifidobacterium lactis), Bifidobacterium infantis (Bifidobacterium lactis), Bifidobacterium adolescentis (Bifidobacterium adolescentis), or a mixture thereof.

According to the most preferred embodiment, as an example, the strains Lactobacillus jensenii NCC 533, Lactobacillus paracasei NCC 2461, Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited under the Budapest treaty at the Pasteur institute (28 rue du Docteur Roux, F-75024 Paris c lex 15) at 6.6.30, 99.1.12, 99.4.15 and 99.3.15, respectively, under accession numbers CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.

Bifidobacterium lactis (ATCC 27536) can also be used as a strain supplied by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O.Box 407, DK-2970 Hoersholm, Denmark).

The probiotic micro-organisms according to the invention may be included in a live, semi-active or inactive form, for example as a lyophilized powder. The culture supernatant of the microorganism may also be included in the product, optionally in concentrated form. It may also be included in encapsulated form. When using a probiotic culture supernatant, the supernatant may be used as such or may be subjected to one or more purification steps to concentrate or isolate the active ingredient/metabolite before being included in the product. Methods and techniques for purifying compounds and assaying the resulting fractions for the activity of the compounds are well known to those skilled in the art.

The probiotic lactic acid bacteria may be present in the carrier in an amount of at least 10⁵cfu/g orally acceptable carrier, preferably about 10⁵To 10¹⁵cfu/g mouthAn orally acceptable carrier, more preferably from 10⁷To 10¹²cfu/g orally acceptable carrier.

It may be incorporated in the form of a dispersion with suitable excipients such as water, organic solvents and fatty substances (including oils), alone or in admixture.

The composition according to the invention also comprises yeast. In a preferred embodiment, the yeast is any food grade yeast selected from Ascomycotina (Ascomycotina) or Deuteromycotina (Deuteromycotina). In a preferred embodiment, the yeast may be selected from the group consisting of Debaryomyces (Debaryomyces), Kluyveromyces (Kluyveromyces), Saccharomyces (Saccharomyces), Yarrowia, Zygosaccharomyces, Candida and Rhoditula, more preferably Saccharomyces cerevisiae (Saccharomyces cerevisiae) (baker's yeast).

Such yeasts can be used in the form of dry or lyophilized extracts. It may be present in the carrier in an amount of at least 10⁵cfu/g orally acceptable carrier, preferably about 10⁵To 10¹⁵cfu/g orally acceptable carrier, more preferably 10⁷To 10¹²cfu/g orally acceptable carrier, the amount depending on the nature and activity of the particular yeast.

Mixtures of various lactic acid bacteria or yeasts may also be used.

The composition may also contain a third photo-protecting agent, preferably at least one carotenoid with or without provitamin A activity, for example, beta-carotene, gamma-carotene, alpha-carotene, lycopene, zeaxanthin and lutein, or mixtures thereof. The carotenoids may be of synthetic or natural origin or contained in natural extracts. When the carotenoid is of natural origin, it is preferably obtained from plant material, wherein the plant is grown in vivo or in vitro. Methods for extracting carotenoids are well known in the art. The carotenoid may be present in the carrier in an amount of 10^-12% to 20% (by weight), preferably 0.00001mg to 50 mg/day, more preferably 0.001mg to 30 mg/day.

The carrier may be any food or pharmaceutical product, or an oral nutritional supplement or oral composition, which may contain probiotic micro-organisms and yeast. Examples of food or pharmaceutical carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk powders, infant formulae or tablets, liquid suspensions, dry oral supplements, wet oral supplements, dry-tube feeding. The oral composition may be in the form of a capsule, soft capsule, tablet, paste or lozenge, gum (gum) or drinkable solution or emulsion. Methods for preparing the carrier are common knowledge.

The compositions according to the invention may also contain usual excipients, in particular sweeteners, flavourings or preservatives.

The compositions according to the invention may be formulated according to any of the techniques well known in the art.

The compositions according to the invention provide a surprising synergistic protective and prophylactic effect on the skin.

Thus, in another aspect, the present invention relates to a method of enhancing the photoprotective function of skin, which comprises orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof and ii) at least one yeast in an orally acceptable carrier.

The amount of the composition to be administered to an individual will depend on the desired effect. However, about 10 is provided per day⁵To 10¹⁵The amount of composition of an individual organism (which may be living or dead) will generally be sufficient.

The composition is administered to an individual prior to or during exposure of the individual to ultraviolet radiation, particularly to sunlight. When the exposure period is predictable, it may be desirable to begin administration before exposure, preferably 1 to 2 months before exposure, and to extend the duration of exposure.

To further illustrate the present invention and its advantages, the following specific examples are given with the understanding that these examples are intended to be illustrative only and not limiting. In the examples that follow, as in the description above, all parts and percentages are by weight unless otherwise indicated.

Examples

In the following examples 1 to 6, beta-carotene was supplied by Roche, lycopene by Lycored, and lyophilized Saccharomyces cerevisiae by BioSpringer, and a dry mixture of Lactobacillus CNCMI-1225, Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 was prepared so that they contained 1X 10⁸To 1X 10⁹An organism.

Example 1

Daily orally administrable photoprotective compositions were prepared as follows:

lyophilized Saccharomyces cerevisiae 75mg

Lactobacillus CNCM I-1225 Dry mixture 50mg

Glucosidex IT 19 (maltodextrin) QSP 500mg

The composition is administered to an individual at a daily dose of 2 x 500mg, which provides a protective and prophylactic effect on the skin.

Example 2

Daily orally administrable photoprotective compositions were prepared as follows:

lyophilized Saccharomyces cerevisiae 75mg

Bifidobacterium CNCM I-2168 dry mixture 50mg

Beta-carotene 4.7mg

Glucosidex IT 19 (maltodextrin) QSP 500mg

The composition is administered to an individual at a daily dose of 2 x 500mg, which provides a protective and prophylactic effect on the skin.

Example 3

Daily orally administrable photoprotective compositions were prepared as follows:

lyophilized Saccharomyces cerevisiae 75mg

Lactobacillus CNCM I-1225 Dry mixture 50mg

Beta-carotene 4.7mg

Lycopene 2.5mg

Glucosidex IT 19 (maltodextrin) QSP 500mg

The composition is administered to an individual at a daily dose of 2 x 500mg, which provides a protective and prophylactic effect on the skin.

Example 4

Daily orally administrable photoprotective compositions were prepared as follows:

lyophilized Saccharomyces cerevisiae 75mg

Lactobacillus CNCM I-2116 dry mixture 50mg

Beta-carotene 4.7mg

Zeaxanthin 10mg

Glucosidex IT 19 (maltodextrin) QSP 500mg

The composition is administered to an individual at a daily dose of 2 x 500mg, which provides a protective and prophylactic effect on the skin.

Example 5

Daily orally administrable photoprotective compositions were prepared as follows:

lyophilized Saccharomyces cerevisiae 75mg

Bifidobacterium CNCM I-216830 mg

Lactobacillus CNCM I-1225 Dry mixture 30mg

Beta-carotene 4.7mg

Lycopene 2.5mg

Glucosidex IT 19 (maltodextrin) QSP 500mg

The composition is administered to an individual at a daily dose of 2 x 500mg, which provides a protective and prophylactic effect on the skin.

Claims (21)

1. An orally administrable composition for the photoprotection of the skin comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof and ii) at least one yeast, included in an orally acceptable carrier.

2. The composition according to claim 1, wherein the lactic acid bacteria are selected from the genus Lactobacillus and/or Bifidobacterium.

3. A composition according to claim 1 or 2, wherein the lactic acid bacterium is Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudostellatum, or a mixture thereof.

4. The composition according to any one of claims 1 to 3, wherein the lactic acid bacterium is CNCMI-1225, CNCM I-2116, CNCM I-2168 or CNCM I-2170.

5. The composition according to any one of claims 1 to 4, wherein the probiotic lactic acid bacteria are included in the carrier in a live, semi-active or inactive form, preferably as a lyophilized powder.

6. The composition according to any one of claims 1 to 5, wherein the yeast is selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhoditolus, or mixtures thereof.

7. The composition according to any one of claims 1 to 6, wherein the yeast is Saccharomyces cerevisiae.

8. A composition according to any one of claims 1 to 7 comprising about 10⁵-10¹⁵cfu/g carrier of lactic acid bacteria.

9. A composition according to any one of claims 1 to 8 comprising about 10⁵-10¹⁵cfu/g vector yeast.

10. A composition according to any one of claims 1 to 9, wherein the carrier is a food or pharmaceutical product, or an oral composition.

11. A composition according to any one of claims 1 to 10, further comprising a third photo-protecting agent, preferably at least one carotenoid.

12. The composition according to claim 10, wherein the food or pharmaceutical carrier is milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk powders, infant formulae or tablets, liquid suspensions, dry oral supplements, wet oral supplements, dry tube fed food.

13. The composition according to claim 10, wherein the oral composition is in the form of a capsule, soft capsule, tablet, paste or lozenge, gum or drinkable solution or emulsion.

14. Use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one yeast, in an orally acceptable carrier, for the preparation of an orally administrable composition for protecting the skin against solar radiation and for reducing or preventing all the related skin disorders.

15. Use according to claim 14, wherein the lactic acid bacterium is Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudostellatum, or a mixture thereof.

16. The use according to claim 14 or 15, wherein the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536.

17. Use according to any one of claims 14 to 16, wherein the yeast is selected from the group consisting of genera debaryomyces, kluyveromyces, saccharomyces, Yarrowia, zygosaccharomyces, candida and rhodulula, or mixtures thereof.

18. Use according to any one of claims 14 to 17, wherein the probiotic lactic acid bacteria are present in the carrier in an amount of about 10⁵To 10¹⁵cfu/g vector.

19. Use according to any one of claims 14 to 17, wherein the yeast is present in the vector in an amount of about 10⁵To 10¹⁵cfu/g vector.

20. A method for improving the photoprotective function of skin, which comprises orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof and ii) at least one yeast in an orally acceptable carrier.

21. A method according to claim 20 wherein the composition is a composition according to any one of claims 1 to 13.